Key Takeaways
- • Congressman Steve Cohen (TN-9) introduced the "Controlled Substances Act Clarification in Sciences Act" on Monday, June 9, 2026, to modernize federal drug policy frameworks and align them with current scientific and pharmacological evidence.
- • The legislation aims to update and clarify the Controlled Substances Act (CSA) definitions and evaluation criteria for regulated substances, reflecting advances in modern science rather than outdated regulatory frameworks.
- • Cohen, a longtime advocate for fair and sensible marijuana policy, has been actively pressing the DEA and Department of Justice to advance cannabis rescheduling, including both medical and recreational use considerations.
- • The proposal represents part of a broader congressional effort to reform drug scheduling and recidivist definitions, with bipartisan sponsorship including Representatives Burchett and Cohen in prior related amendments.
Summary
Congressman Steve Cohen introduced legislation on Monday to reform the federal Controlled Substances Act, marking a significant push toward modernizing U.S. drug policy. The "Controlled Substances Act Clarification in Sciences Act" seeks to update and clarify the CSA so that its substance classifications and evaluation standards reflect contemporary scientific and pharmacological research rather than legacy regulatory frameworks.
Cohen, representing Tennessee's 9th District, has established himself as a prominent voice on drug policy reform, particularly regarding cannabis. He welcomed the Department of Justice's decision to reschedule medical marijuana but has consistently advocated for further action on recreational use. According to his official House correspondence, Cohen has directly urged DEA Administrator Anne Milgram to accelerate the agency's recommendation for cannabis rescheduling, signaling legislative pressure on executive branch action.
The legislation addresses definitional clarity within the CSA's framework. Related amendments previously sponsored by Representatives Burchett and Cohen sought to clarify the definitions of different types of recidivist offenses under federal drug laws, indicating a pattern of legislative focus on both scheduling and sentencing precision. The broader objective reflects recognition that the CSA, which establishes a unified legal framework to regulate substances deemed to pose public health risks, has not kept pace with scientific advances and current understanding of drug pharmacology.
This initiative arrives amid ongoing regulatory activity around cannabis and synthetic substances. Recent federal actions, including the HALT Fentanyl Act signed into law on July 16, 2025, demonstrate continued congressional engagement with controlled substances policy. Cohen's proposal positions reform not as deregulation but as evidence-based recalibration—aligning federal law with modern science to ensure fairness and accuracy in national drug policy. The legislative effort reflects broader institutional pressure for CSA modernization driven by evolving scientific consensus and changing state-level cannabis policies.
Cohen, representing Tennessee's 9th District, has established himself as a prominent voice on drug policy reform, particularly regarding cannabis. He welcomed the Department of Justice's decision to reschedule medical marijuana but has consistently advocated for further action on recreational use. According to his official House correspondence, Cohen has directly urged DEA Administrator Anne Milgram to accelerate the agency's recommendation for cannabis rescheduling, signaling legislative pressure on executive branch action.
The legislation addresses definitional clarity within the CSA's framework. Related amendments previously sponsored by Representatives Burchett and Cohen sought to clarify the definitions of different types of recidivist offenses under federal drug laws, indicating a pattern of legislative focus on both scheduling and sentencing precision. The broader objective reflects recognition that the CSA, which establishes a unified legal framework to regulate substances deemed to pose public health risks, has not kept pace with scientific advances and current understanding of drug pharmacology.
This initiative arrives amid ongoing regulatory activity around cannabis and synthetic substances. Recent federal actions, including the HALT Fentanyl Act signed into law on July 16, 2025, demonstrate continued congressional engagement with controlled substances policy. Cohen's proposal positions reform not as deregulation but as evidence-based recalibration—aligning federal law with modern science to ensure fairness and accuracy in national drug policy. The legislative effort reflects broader institutional pressure for CSA modernization driven by evolving scientific consensus and changing state-level cannabis policies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.